BC
SAGE

Brinker Capital’s Sage Therapeutics SAGE Stock Holding History

Brinker Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,282
Closed -$237K – 979
2019
Q4 		$237K Sell
3,282
-3,434
-51% -$422K 0.01% 900
2019
Q3 		$942K Buy
6,716
+240
+4% +$40.1K 0.03% 501
2019
Q2 		$1.19M Sell
6,476
-295
-4% -$50.3K 0.04% 414
2019
Q1 		$1.08M Buy
6,771
+3,102
+85% +$449K 0.04% 436
2018
Q4 		$351K Sell
3,669
-1,417
-28% -$162K 0.02% 701
2018
Q3 		$718K Buy
5,086
+242
+5% +$37.4K 0.03% 596
2018
Q2 		$758K Buy
+4,844
New +$760K 0.03% 576
2018
Q1 		– Sell
-2,447
Closed -$403K – 1020
2017
Q4 		$403K Buy
+2,447
New +$237K 0.02% 758

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Brinker Capital's SAGE Position: Q1 2020 in Review

Brinker Capital sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 3,282 shares — an estimated $237K sold.

Brinker Capital first reported a position in SAGE in Q4 2017 and held it in 8 quarters. The position peaked at $1.19M in Q2 2019. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Brinker Capital reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Brinker Capital sold 3,282 Sage Therapeutics shares in Q1 2020, an estimated $237K.
  • Brinker Capital first reported a position in Sage Therapeutics in Q4 2017 and held it in 8 quarters.
  • Brinker Capital's Sage Therapeutics position peaked at $1.19M in Q2 2019.
  • 230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Brinker Capital's 13F filing for Q1 2020, filed 29 Apr 2020.